Sia Daneshmand, MD, discusses the groundbreaking findings from the SunRISe-1 study, highlighting TAR-200’s impressive complete response rates as a monotherapy for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Dr. Daneshmand describes how TAR-200’s sustained drug delivery sets it apart from conventional intravesical therapies, offering a promising new approach to bladder-sparing strategies. He delves into the study’s safety, tolerability, and durable responses, as well as its potential to supplement or delay the need for radical cystectomy in eligible patients. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
Latest News
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.